The Belgian Red Cross is a leading independent humanitarian organisation in Belgium and part of the International Red Cross and Red Crescent Movement, founded in 1864. Building on its longstanding expertise in blood processing, Belgian Red Cross developed Lysantum®, a patented human platelet lysate (HPL) produced from surplus donor platelets as a xeno-free alternative to Fetal Bovine Serum (FBS). Manufactured under GMP-aligned conditions with full European donor traceability, Lysantum offers high consistency, safety, and scalability. Its fibrinogen-depleted, pathogen-inactivated formulation supports robust and reproducible cell expansion across multiple cell types. With reliable supply and growth kinetics up to twice as fast as FBS, Lysantum enables more efficient and cost-effective cell culture development.